Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Esophageal Neoplasms 4Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Adenocarcinoma 2Solid Tumor 1Rectal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Pathologic Complete Response 1Neoplasms, Unknown Primary 1Nasopharyngeal Carcinoma 1Locally Advanced Gastric Adenocarcinoma 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × tegafur-gimeracil-oteracil × Clear all
NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡